OPKO Health subsidiary ModeX Therapeutics has started dosing patients with its tetraspecific T-cell engager, MDX2003, for ...

Scott McCarron eats right, sleeps well and tries to stay in great shape. He won three times on the PGA Tour and has won 11 ...

Patients dosed in Phase 1 safety and tolerability study of MDX2003, a novel T-cell engager designed to optimize killing of lymphomasPreclinical ...

Metabolic tumor volume--a biomarker derived from PET imaging--can more accurately predict progression-free survival for large ...

Preclinical data showed enhanced anti-tumor activity and reduced cytokine release compared to conventional single-chain CAR T approaches -- Early clinical case from CELESTIAL-301 trial, the ...

Researchers assessed whether using bispecific antibodies targeting CD20 and CD3 would reduce efficacy or increase toxicity in patients with relapsed or refractory non-Hodgkin B-cell lymphomas ...

Lymphocyte growth rate after CAR-T therapy predicts survival and toxicity in lymphoma. Discover how this biomarker could ...

Scott McCarron was diagnosed with B-cell lymphoma and is playing this week's PGA Tour Champions event despite starting ...

ModeX Therapeutics initiates clinical trial of tetraspecific antibody for treatment of B-cell lymphomas: Weston, Massachusetts Friday, April 24, 2026, 16:00 Hrs [IST] ModeX Therap ...

For a man with three PGA Tour wins and a decorated Champions circuit career, Scott McCarron’s toughest fight began not on the ...

First-in-human clinical trial underway to evaluate safety, tolerability and pharmacodynamic activity of HB2198 in normal healthy volunteers. A ...

Researchers found that loss of HDAC7 disrupted B-cell maturation in mouse models. Restoring HDAC7 suppressed tumor growth, ...